Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, today reported financial results and key ...

In April 2024, Entera announced that the Journal of Bone and Mineral Research (JBMR) published EB613 placebo controlled Phase 2 Trial results, highlighting its dual mechanism of action and rapid ...

OPKO Health, Inc. OPK is well-poised for growth in the coming quarters, courtesy of its potential in RAYALDEE. The optimism ...

Bank Leumi led trading today, and rose 1.28%. Elbit Systems rose 2.48%; Bank Hapoalim rose 0.14%; Discount Bank fell 0.04%; and ICL fell 0.86%.

Investors who take an interest in OPKO Health, Inc. (NASDAQ:OPK) should definitely note that the Chairman & CEO, Phillip Frost, recently paid US$1.74 per share to buy US$348k worth of the stock.

HC Wainwright reiterated their buy rating on shares of OPKO Health (NASDAQ:OPK – Free Report) in a research report sent to investors on Wednesday morning,Benzinga reports. The brokerage currently has ...

OPKO Health (NASDAQ: OPK) has recently received a number of price target changes and ratings updates: 3/19/2025 – OPKO Health ...

OPKO Health and Entera Bio, a developer of oral peptides and protein replacement therapies, entered into a license agreement ...

On the foreign exchange market, the representative shekel-US dollar exchange rate was set 0.05% higher, at 3.6650/$, and the representative shekel-euro rate was set 0.36% higher, at 4.0073/€.

Opko Health and Entera Bio have announced a partnership and licence agreement to progress the development of the first oral ...

Under the terms of the agreement, OPKO will accept 60% of the development costs, while Entera will shoulder 40%.

US biotech OPKO Health (Nasdaq: OPK) and Israeli firm Entera Bio (Nasdaq: ENTX) have entered into a collaboration to develop an oral GLP-1/glucagon dual agonist tablet for obesity, metabolic ...